1-3 of 3
C. Daniel Kingsley
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL

Clinical Trials & Observations
Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, Jamie Hirata, Tammy McIver, Rodica Morariu-Zamfir, Thomas J. Kipps
Journal: Blood
Blood (2019) 133 (9): 990–992.
https://doi.org/10.1182/blood-2018-06-857714
Published: 2019
Journal Articles

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

Clinical Trials & Observations
Jennifer R. Brown, Susan O’Brien, C. Daniel Kingsley, Herbert Eradat, John M. Pagel, James Lymp, Jamie Hirata, Thomas J. Kipps
Journal: Blood
Blood (2015) 125 (18): 2779–2785.
https://doi.org/10.1182/blood-2014-12-613570
Published: 2015
Journal Articles

Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GAO4779g)

Jennifer R Brown, MD, PhD, Susan O'Brien, MD, C Daniel Kingsley, MD, FACP, Herbert Eradat, MS, MD, John M. Pagel, MD, PhD, James Lymp, PhD, Jamie Hirata, PharmD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 523.
https://doi.org/10.1182/blood.V122.21.523.523
Published: 2013